Understanding ST7-OT3: A Non-Coding RNA Molecule as A Potential Drug Target

Target Name: ST7-OT3

NCBI ID: G93655

ST7-OT3

Other Name(s): NCRNA00026 | ST7OT3 | ST7 overlapping transcript 3 | ST7

Understanding ST7-OT3: A Non-Coding RNA Molecule as A Potential Drug Target

ST7-OT3, also known as NCRNA00026, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization have made it an attractive target for researchers to investigate, and its potential utility as a therapeutic agent has led to a growing body of research.

ST7-OT3 is a small non-coding RNA molecule that is expressed in most tissues and cells of the body. It is characterized by its unique structure, which consists of a long stem-like region that is connected to a short terminal region that contains aConserved RNA-binding protein (RBP) binding site. RBP is a transcription factor that binds to specific sequences on ST7-OT3, thereby regulating its stability, expression levels, and interactions with other molecules.

The subcellular localization of ST7-OT3 has also attracted the attention of researchers. In a variety of tissues, ST7-OT3 is mainly distributed in neurons and glial cells. These cell types play important physiological functions in the nervous system. In addition, ST7-OT3 is mainly distributed in the liver and kidneys. These organs are mainly responsible for removing toxins and metabolic waste in the body. These subcellular localization results indicate that ST7-OT3 plays an important role in important physiological processes such as the nervous system and urinary system, and therefore has high strategic value.

The pharmacological properties of ST7-OT3 have also attracted widespread attention. Studies have shown that ST7-OT3 has a variety of biological activities, including inhibiting neuronal synaptic growth, promoting neuronal apoptosis, and regulating neuronal synaptic plasticity. These biological activities make ST7-OT3 a potential drug target. At present, some studies have explored the effect of ST7-OT3 as a therapeutic target for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, etc. In addition, ST7-OT3 is also used as a therapeutic target for tumors and the immune system, such as inhibiting tumor cell growth and enhancing immune cells to kill tumor cells.

In addition to its potential value in drug research and biomarker research, ST7-OT3 also has important clinical application prospects. As the population ages and the incidence of neurodegenerative diseases increases, developing drugs to treat these diseases has huge social and economic benefits. As an important molecule, ST7-OT3 can be used to develop new drugs for the treatment of neurodegenerative diseases, thereby improving the quality of life and extending lifespan of patients.

In summary, ST7-OT3 is a non-coding RNA molecule with significant pharmacological value and clinical application prospects. With the deepening of research, ST7-OT3 will become an important drug target and provide new ideas and methods for the treatment of neurodegenerative diseases and other diseases.

Protein Name: ST7 Overlapping Transcript 3

The "ST7-OT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST7-OT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets